These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 31543676)

  • 1. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation.
    Nicoletti A; Ponziani FR; Biolato M; Valenza V; Marrone G; Sganga G; Gasbarrini A; Miele L; Grieco A
    World J Gastroenterol; 2019 Sep; 25(33):4814-4834. PubMed ID: 31543676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver cirrhosis and complications from the perspective of dysbiosis.
    Nie G; Zhang H; Xie D; Yan J; Li X
    Front Med (Lausanne); 2023; 10():1320015. PubMed ID: 38293307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.
    Pierantonelli I; Rychlicki C; Agostinelli L; Giordano DM; Gaggini M; Fraumene C; Saponaro C; Manghina V; Sartini L; Mingarelli E; Pinto C; Buzzigoli E; Trozzi L; Giordano A; Marzioni M; Minicis S; Uzzau S; Cinti S; Gastaldelli A; Svegliati-Baroni G
    Sci Rep; 2017 Sep; 7(1):12200. PubMed ID: 28939830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota-related complications in cirrhosis.
    Gómez-Hurtado I; Such J; Sanz Y; Francés R
    World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
    Utzeri E; Usai P
    World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
    J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
    Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
    Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.
    Chen D; Le TH; Shahidipour H; Read SA; Ahlenstiel G
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and the liver.
    Federico A; Dallio M; Caprio GG; Ormando VM; Loguercio C
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):385-398. PubMed ID: 28927250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.
    Shao T; Zhao C; Li F; Gu Z; Liu L; Zhang L; Wang Y; He L; Liu Y; Liu Q; Chen Y; Donde H; Wang R; Jala VR; Barve S; Chen SY; Zhang X; Chen Y; McClain CJ; Feng W
    J Hepatol; 2018 Oct; 69(4):886-895. PubMed ID: 29803899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut Microbiota and Complications of Liver Disease.
    Acharya C; Bajaj JS
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
    Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
    Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.
    Schneider KM; Mohs A; Kilic K; Candels LS; Elfers C; Bennek E; Schneider LB; Heymann F; Gassler N; Penders J; Trautwein C
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature.
    Pijls KE; Jonkers DM; Elamin EE; Masclee AA; Koek GH
    Liver Int; 2013 Nov; 33(10):1457-69. PubMed ID: 23879434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.